You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Funded Biomarker Testing

Find an overview of funded biomarker testing in Ontario. Information listed includes diagnostic, predictive and prognostic markers, as well as a summary of testing sites.

Disponible en anglais seulement. Vous pouvez demander un version française.

Funded Biomarker Testing

5 items

Newly diagnosed cases of squamous cell carcinoma where HPV cannot be determined from histology/p16 staining.

Funded Biomarker Disease Site: Head and Neck
Biomarker: HPV
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, University Health Network

Reflex testing on newly diagnosed tumours with metastatic, unresectable recurrent head and neck squamous cell carcinoma.

Funded Biomarker Disease Site: Head and Neck
Biomarker: PD-L1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hamilton Health Sciences, Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Mount Sinai Hospital, St. Joseph's Healthcare Hamilton, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, University Health Network, William Osler Health System

Testing on all sinonasal carcinoma where HPV and EBV have been excluded

Funded Biomarker Disease Site: Head and Neck
Biomarker: SMARCA4, SMARCB1
Testing Method:Immunohistochemistry (IHC)
Testing Site: Hospital for Sick Children (SickKids), William Osler Health System

Testing on all sinonasal carcinoma where HPV and EBV have been excluded, and with retained/equivocal SMARC immunohistochemistry test results.

Funded Biomarker Disease Site: Head and Neck
Biomarker: DEK-AFF2, EWSR1-FLI, EGFR, IDH2, NUTM1, PAX3, PAX7
Testing Method:Sequencing
Testing Site: Hospital for Sick Children (SickKids), University Health Network

Testing to support diagnosis of nasopharyngeal carcinoma (newly diagnosed or suspected nasopharyngeal carcinoma).

Funded Biomarker Disease Site: Head and Neck
Biomarker: EBER
Testing Method:In Situ Hybridization (ISH)
Testing Site: Health Sciences North, Kingston Health Sciences Centre, London Health Sciences Centre, Markham Stouffville Hospital (Oak Valley Health), Mount Sinai Hospital, Sunnybrook Health Sciences Centre, The Ottawa Hospital, Trillium Health Partners, Unity Health - St. Michael's Hospital, University Health Network, William Osler Health System